Author Archives: admin


Stem Cell Clinic > Articles by: admin

The Global Stem Cell Therapy Market Growth To 2023 Will Be Driven By Increasing Prevalence Of Chronic Diseases – Press Release – Digital Journal

By Stem Cell Treatment

"Global Stem Cell Therapy Market, Forecast Market Size, 2019 2023, $ Billion"

The Business Research Companys Global Stem Cell Therapy Market Report 2020-30: Covid 19 Growth And Change; Segments Covered: 1) By Type: Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy 2) By Cell Source: Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells 3) By Application: Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, Others 4) By End-User: Hospitals, Clinics

The global stem cell therapy market is expected to decline from $8.73 billion in 2019 to $8.62 billion in 2020 at a compound annual growth rate (CAGR) of -1.24%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The global stem cell therapy market is then expected to recover and reach $14.76 billion in 2023 at a CAGR of 19.62%.

The rising prevalence of chronic diseases contributed to the stem cell therapy market growth. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases among people, thus driving the need for stem cell therapy. According to a United Nations article, by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic diseases is expected to reach about 60%. The rising prevalence of chronic diseases is expected to drive the global stem cell therapy market growth.

Companies in the stem cell therapy market are increasingly investing in strategic partnerships. The strategic partnership is a mutually beneficial agreement between two companies that do not compete directly with each other. For instance, in September 2018, CRISPR Therapeutics, a biotechnology company that develops transformative medicine using the gene-editing platform for serious diseases, and ViaCyte, a California-based regenerative medicine company, collaborated for the development and commercialization of allogeneic stem cell therapies for diabetes treatment.

The high cost of stem cell therapy is expected to limit the growth of the stem cell therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for chronic diseases has impacted the health conditions of the population and has led to a low average life expectancy. According to the DVCSTEM, the average cost of stem cell therapy in the USA is between $20,000 to $25,000, in Mexico, it is $33,000, in Central America, it is $30,000, and in Asia, it is $50,000, thus restraining the growth of the market.

The stem cell therapy market consists of the sales of stem cell therapy and related services by entities (organizations, sole traders, and partnerships) that provide stem cell therapy. Stem cell therapy, also known as regenerative medicine, promotes the repair response of a diseased patient, or a dysfunctional or injured tissue using stem cells or their derivatives.

Here Is A List Of Similar Reports By The Business Research Company:

Cell Therapy Market Global Report 2020-30: Covid 19 Growth And Change

Stem Cell/Cord Blood Banking Global Market Report 2020-30: Covid 19 Growth And Change

Plasma Therapy Global Market Report 2020-30: Covid 19 Growth And Change

Interested to know more about The Business Research Company? The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Media Contact Company Name: The Business Research Company Contact Person: Oliver Guirdham Email: Send Email Phone: +44 20 7193 0708 Address: City: London State: Greater London Country: United Kingdom Website: https://www.thebusinessresearchcompany.com/

Originally posted here:
The Global Stem Cell Therapy Market Growth To 2023 Will Be Driven By Increasing Prevalence Of Chronic Diseases - Press Release - Digital Journal

Mesoblast hit by FDA rejection, request to run another trial – FierceBiotech

By Stem Cell Treatment

The FDA has issued (PDF) a complete response letter to Mesoblasts request for approval of allogeneic cell therapy remestemcel-L in children with steroid-resistant graft-versus-host disease. FDA officials want to see data from at least one additional clinical trial before granting full authorization, but Mesoblast is still hoping to snag an accelerated approval using its existing data.

Evidence of the FDAs concerns with Mesoblasts remestemcel-L filing emerged in August when the agency released a briefing document to inform a discussion of the application by the Oncologic Drugs Advisory Committee (ODAC). The FDA cited multiple perceived shortcomings of the filing, arguing for example that the ability of the mesenchymal stem cell therapy to reduce inflammation as measured by inflammatory biomarkers in humans receiving the product has not been demonstrated.

Despite the FDAs concerns, ODAC members voted nine to one that the data support the efficacy of remestemcel-L in children with steroid-resistant graft-versus-host disease. The positive ODAC vote sent shares in Mesoblast, which had been depressed by the briefing document, up 50%.

Join a panel of experts as they discuss the rigor involved in optimizing and scaling a reproducible serological assay for COVID-19.

However, the ODAC vote was advisory, and the FDA, in a rare but far from unprecedented action, has chosen to go against the recommendation of the committee. Shares in Mesoblast fell 37% in response to the rejection, sinking back to the low they hit in the wake of the briefing document.

Mesoblast said the FDA has recommended it runs at least one additional randomized clinical trial in adults or children with steroid-resistant graft-versus-host disease before refiling for approval. The recommendation suggests Mesoblast will need to expend time and money to get remestemcel-L to market. The phase 3 trial cited in the briefing document lasted almost three years.

However, Mesoblast is holding out hope that it can get remestemcel-L to some patients without the extra data requested by the FDA. In light of the unmet medical need, Mesoblast plans to request a Type A meeting with FDA to discuss the possibility of an accelerated approval. Mesoblast is hoping the FDA will agree to authorize remestemcel-L on the proviso that it runs a study post-approval.

If Mesoblast is to persuade the FDA to grant remestemcel-L accelerated approval, it may need to address some of the agencys other concerns. Mesoblast said the FDAs response letter identified the need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.

The comment reflects sections of the briefing document in which the FDA said the quality attributes lack a demonstrated relationship to the clinical performance of specific [drug product] lots. In the absence of evidence of that relationship, the FDA said the attributes may not be sufficient to ensure the manufacturing process consistently produces remestemcel-L lots of acceptable quality.

In disclosing the response letter, Mesoblast said assays measuring the potency of remestemcel-L will continue to be refined to provide further scientific rationale for its use in severe inflammatory diseases with high mortality risk.

See more here:
Mesoblast hit by FDA rejection, request to run another trial - FierceBiotech

First Man Cured of AIDS Dies From Cancer – The Keystone Newspaper

By Stem Cell Treatment

Featured

By Dylan Adams News Editor

Timothy Ray Brown, the first known person to be cured of HIV, died on Sept. 29 at age 54 after battling cancer.

Timothy Ray Brown, a figurehead in the AIDS and HIV community, passed away surrounded by friends after a five-month battle with leukemia, stated Tim Hoeffgen, Browns partner.

Brown received a positive HIV diagnosis in 1995 while studying in Berlin.

In 2006, Brown was diagnosed with acute myeloid leukemia, which is a cancer that builds in the bone marrow and blood interfering with blood cell production. After bouts of infections from several rough rounds of chemotherapy, Browns leukemia came out of remission.

Due to leukemia in his bones, Brown required a stem cell transplant, a process that allows healthy stem cells to be introduced into a host to stimulate the immune system and healthy bone marrow growth. At the time, the survival rates for stem cell transplant were around fifty percent.

Doctors found a match to Browns genetic type, a donor with the CCR5 Delta 32 mutation, a protein that acts as a doorway to stop the HIV from infecting new cells. Three months after Brown stopped taking his HIV medication, doctors found he no longer had HIV in his blood.

After another round of stem cell treatment in February of 2008, Brown went through several near-death complications, almost going blind and becoming paralyzed but slowly recovering. His body was still successfully fighting off HIV.

In July 2012, the Timothy Ray Brown Foundation was created during the World AIDS Conference in Washington, DC. This foundation was built for Brown to show his support and work with medical institutions and scientists to develop a unifying cure and vaccination against HIV.

Brown would often donate large amounts of blood and tissue samples to researchers in the hope of progressing closer towards an HIV cure. According to his partner, Hoeffgen, Tims lifework was to tell his story about his HIV cure and become an ambassador of hope to those in need.

Doctors have since used Brown as a blueprint to work on a potential cure and vaccine for HIV. Most notably for the second person to ever be cured of HIV the London Patient, Adam Castillejo who went through similar stem cell transplants in 2019 before coming forward to the public.

Like Loading...

See original here:
First Man Cured of AIDS Dies From Cancer - The Keystone Newspaper

Avrobio bags gene therapy to join Regenxbio and Sangamo in race – FierceBiotech

By Stem Cell Treatment

Avrobio has licensed a Hunter syndrome lentiviral gene therapy from the University of Manchester in the U.K. The deal positions Avrobio to join Regenxbio and Sangamo Therapeutics in the race to develop gene therapies for use in patients with the rare disorder.

Hunter syndrome, also known as mucopolysaccharidosis Type II, is driven by a mutation that limits a patients ability to break down sugar molecules generated as a byproduct of cell activity. The buildup of the molecules causes progressive damage to organs such as the brain, affecting the development of children with the lysosomal disorder.

Takedas approved drug Elaprase gives Hunter syndrome patients the enzyme they need to break the molecules down, but its inability to cross the blood-brain barrier renders it ineffective against the CNS manifestations of the disease.

Join a panel of experts as they discuss the rigor involved in optimizing and scaling a reproducible serological assay for COVID-19.

Avrobio has become the latest company to identify gene therapy as a potentially better way to treat Hunter syndrome. The biotech, which is active in other lysosomal disorders, has agreed to pay the University of Manchester $8 million upfront for the global rights to a stem cell gene therapy that is set to enter the clinic in the second half of next year.

Brian Bigger, Ph.D., a professor of cell and gene therapy at the U.K. university, developed the candidate and co-authored a paper about it in 2018. The paper describes work on a braintargeted hematopoietic stem cell gene therapy designed to give patients the lysosomal enzyme iduronate-2-sulfatase (IDS).

Avrobio will make the therapy, now called AVR-RD-05, by modifying a patients own hematopoietic stem cells with a transgene for IDS expression and a protein tag intended to improve stability of the enzyme. If AVR-RD-05 works as hoped, the cells will engraft in the bone marrow and make copies of themselves that also carry the transgene.

The differentiation of the cells into components of the immune system could enable AVR-RD-05 to cause a lasting, body-wide increase in the presence of the enzyme at the root of Hunter syndrome. Avrobio will fund a 9.1 million ($11.8 millon) investigator-sponsored phase 1/2 trial to assess whether the gene therapy performs as hoped. The biotech is also on the hook for up to $80 million in milestones.

Avrobio will face competition if it gets AVR-RD-05 all the way to market. Takeda is the incumbent, Regenxbio and Sangamo have gene therapies in the clinicalthough the latter has underwhelmed so farand Denali Therapeutics is developing an IDS enzyme designed to cross the blood-brain barrier.

Read the rest here:
Avrobio bags gene therapy to join Regenxbio and Sangamo in race - FierceBiotech

FDA Grants Breakthrough Therapy Designation to CD123-Directed Antibody-Drug Conjugate – Targeted Oncology

By Stem Cell Treatment

The FDA has granted a Breakthrough Therapy designation to IMGN632 as treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasms (BPDCN), ImmunoGen, Inc., announced in a press release.

We are pleased FDA has granted Breakthrough Therapy designation for IMGN632, our novel CD123-targeted ADC, as it underscores the urgent need for effective and well-tolerated treatments for patients with this rare and aggressive cancer, said Mark Enyedy, president and chief executive officer, ImmunoGen, in a statement. We look forward to continuing to work with FDA to further define the development path for IMGN632 in BPDCN, in addition to pursuing our ongoing evaluation of IMGN632 in AML and other hematological malignancies.

IMGN632, a CD123-targeting antibody-drug conjugate (ADC), is in clinical development for the treatment of hematologic malignancies like BPDCN, acute myeloid leukemia (AML), and acute lymphocytic leukemia in clinical trials. The agent is under evaluation as monotherapy in patients with BPDCN and minimal residual disease (MRD)-positive AML after induction treatment, as well as in combination with venetoclax (Venclexta) plus azacitidine (Vidaza) in patients with relapsed/refractory AML.

BPDCN, a rare blood cancer, is known to have features associated with both leukemias and lymphomas, with characteristic skin lesions, lymph node involvement, and frequent spread to the bone marrow. This is an aggressive cancer that requires intense treatment regimens that are often followed by stem cell transplantation. This represents a patient population of unmet need, particularly those in the relapsed/refractory setting.

The phase 1/2 open-label, multicenter clinical trial of IMGN632 plus venetoclax and azacitidine is investigating the safety and efficacy, as well as assess the antileukemic activity of the combination in patients with relapsed assessed in frontline CD123-positive AML. The antileukemia activity of the monotherapy will also be assessed in patients with MRD-positive AML.

The primary end points of the study include safety and tolerability, preliminary antileukemia activity, and MRD levels. The study is currently recruiting and is exploring several different doses of the ADC. IMGN632 will be assessed in combination and monotherapy across multiple regimen arms. Arm A will assess azacitidine, arm B venetoclax, arm C azacitidine plus venetoclax, and arm D will evaluate IMGN632 monotherapy in patients with MRD+ AML.

For arms A through C, a phase 1b dose-escalation cohort in arms A through C will determine the recommended phase 2 dose, and a phase 2 dose-expansion phase will further evaluate each regimen in arms A through D to characterize the safety profile and assess the antileukemia activity. Arm D will open with a dose-expansion cohort, using the ADC monotherapy dose and schedule based on the findings from the initial phase 2 IMGN632-0801 study, and there will be no dose-escalation portion.

To be included in the trial, patients must be at least 18 years of age, have a confirmed AML diagnosis, and be deemed appropriate for this experimental therapy per the treating physician. Patients must have CD123-positive AML to be included in the study, and they were allowed to have received prior CD123-targeted therapies, as long as they have not received IMGN632. Patients had to have an ECOG performance status 1 and resolution of any prior treatment-related toxicities to either grade 1 or baseline.

Patients cannot have received any anticancer therapy within 14 days before administration of the study drug, prior IMGN632 therapy, a myeloproliferative neoplasm-related secondary AML, or active central nervous system AML. They are also ineligible if they have a history of sinusoidal obstruction syndrome/venous occlusive disease of the liver, myocardial infarction within 6 months of enrollment, or clinically relevant active infection, including known active hepatitis B or C, HIV infection, cytomegalovirus, or other infectious diseases that would make the patient inappropriate for enrollment to this study.

Reference

ImmunoGen announces FDA breakthrough therapy designation for IMGN632 in relapsed or refractory blastic plasmacytoid dendtritic cell neoplasm. News Release. ImmunoGen, Inc. October 5, 2020. Accessed October 5, 2020. https://bit.ly/3ljtSFt

Originally posted here:
FDA Grants Breakthrough Therapy Designation to CD123-Directed Antibody-Drug Conjugate - Targeted Oncology

Animal Stem Cell Therapy Market – Great Growth Opportunities for the Market in the Coming Year | TMR Research Study – BioSpace

By Stell Cell Research

Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans. Stem cell therapy has also acquired a prominent place in the veterinary sector.

The influence of animal stem cell therapy for the treatment of various animals for diverse diseases and disorders is growing rapidly. Therefore, this factor may help the global animal stem cell therapy market to generate exponential growth across the forecast period of 2019-2029. Stem cells help in the replacement of neurons affected by stroke, Parkinsons disease, spinal cord injury, Alzheimers disease, and others.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6816

This animal stem cell therapy market report has extensive information on various aspects associated with bringing growth. Important factors such as emerging trends, mergers and acquisitions, and the regional scenario of the animal stem cell therapy market have been analyzed and included in the report. The stakeholders can derive a treasure of information from this report. This report also includes a scrutinized take on the COVID-19 impact on the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Competitive Prospects

The competitive landscape of the animal stem cell therapy market can be described as mildly fragmented. With a considerable chunk of players, the animal stem cell therapy market is surrounded by substantial competition. Research and development activities form an important part of the growth landscape because they help gain novel insights.

Activities such as mergers, acquisitions, joint ventures, collaborations, and partnerships form the foundation of the growth of the animal stem cell therapy market. These activities help manufacturers to gain influence and eventually help in increasing the growth rate of the animal stem cell therapy market. Prominent participants in the animal stem cell therapy market are Magellan Stem Cells, Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc., Celavet Inc., VETSTEM BIOPHARMA, and VetCell Therapeutics.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6816&ltype=S

Animal Stem Cell Therapy Market: Key Trends

Infections are scaling up among animals at a rapid rate. The alarming increase is proving fatal for many animals. Therefore, to avoid such incidences and treat existing diseases and disorders, animal stem cell therapy is being applied seamlessly. Hence, this aspect may bring great growth opportunities for the animal stem cell therapy market.

Developments have been observed across the animal stem cell therapy market for long. Autologous adipose-derived mesenchymal stem cells are gaining traction for successfully resolving a range of issues in animals. These stem cells help in treating ligament and tendon injuries to a certain extent. The strengthening influence of this stem cell type in companion animals is also proving to be a prominent growth prospect for the animal stem cell therapy market.

Recent research has also found that stem cell-derived CC exosomes showed improved recovery from myocardial infarction (MI) among pigs. Such developments assure promising growth for the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Regional Analysis

The animal stem cell therapy market is spread across North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The animal stem cell therapy market may derive significant growth from North America. The escalating awareness regarding animal stem cell therapy may attract profound growth. Strengthening research and development activities in the region regarding animal stem cell therapy is further expanding the growth prospects.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6816

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

View original post here:
Animal Stem Cell Therapy Market - Great Growth Opportunities for the Market in the Coming Year | TMR Research Study - BioSpace

Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -…

By Stell Cell Research

Gosselies, Belgium, 5 October 2020, 7am CEST BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, Link Health Pharma Co., Ltd (Link Health) and Shenzhen Pregene Biopharma Company, Ltd (Pregene) today announce the signing of an exclusive license agreement for the manufacturing, clinical development and commercialization of Bone Therapeutics allogeneic, off-the-shelf, bone cell therapy platform ALLOB in China (including Hong Kong and Macau), Taiwan, Singapore, South Korea, and Thailand.

Under the agreement, Bone Therapeutics is eligible to receive up to 55 million in development, regulatory and commercial milestone payments including 10 million in upfront and milestone payments anticipated in the next 24 months. Bone Therapeutics is also entitled to receive tiered double-digit royalties on annual net sales of ALLOB. Bone Therapeutics retains development and commercialization rights to ALLOB in all other geographies outside of those covered by this agreement. As a result, Bone Therapeutics will continue to concentrate on its development and commercialization plans for ALLOB in the US and Europe and novel innovative cell-based products globally.

This collaboration between Bone Therapeutics, Link Health and Pregene expands our geographic reach and demonstrates the global commercial potential of ALLOB,said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. We already have operational experience in Asia with the Phase III clinical trial of our lead product JTA-004 in Hong Kong. We selected Link Health and Pregene to partner with us in Asia as a result of their expertise in advanced therapeutics and cell therapies, their proven track record of development and commercial implementation in Chinese and Asian markets, and Pregenes well established cell therapy manufacturing capacity. Bone Therapeutics will continue to develop the ALLOB cell therapy platform for other markets while exploring additional partnership opportunities in the U.S. and Europe.

The agreement grants Link Health and Pregene exclusive rights to clinically develop and commercialize ALLOB for the treatment of human bone disorders in Greater China, Taiwan, Singapore, South Korea, and Thailand. All rights for China will be transferred to Pregene and Link Health will gain rights for the remaining countries Bone Therapeutics will share its patented proprietary manufacturing expertise for the expansion and differentiation of bone-forming cells and has the option to sell clinical supplies to Link Health and Pregene in preparation for their clinical development of ALLOB.

This collaboration and license agreement for Bone Therapeutics ALLOB provides a strong addition to our pipeline. ALLOB has demonstrated the potential to reduce the recovery time and stimulate bone growth for a variety of bone conditions, and to have a considerable impact on patients lives,said Yan Song, PhD, Chief Executive Officer of Link Health. It is important for Link Health to collaborate with companies that have strong therapeutic product portfolios and entrepreneurial management. This partnership with Bone Therapeutics is a direct result of our shared commitment to appreciate the enormous potential of cell therapy and regenerative medicine.

Pregene now has a flourishing portfolio of CAR-T cell therapy-based cancer treatments. Bone Therapeutics ALLOB provides anallogeneic, off-the-shelf cell therapy that expands our portfolio of cell therapies to include the sizable commercial potential of orthopedics,said Hongjian Li, Co-founder and Chief Executive Officer of Pregene. We expect to be able to leverage our extensive international cell and gene therapy experience to develop Bone Therapeutics ALLOB platform and subsequently launch products in China and Southeast Asian markets.

ALLOB, an allogeneic and off-the-shelf cell therapy product manufactured through a proprietary, scalable production process, consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors. In preclinical studies ALLOB has shown to reduce healing time in a delayed-union fracture model by half, and has demonstrated good tolerability and signs of efficacy in two Phase IIa studies for two separate indications. The Companys randomized, placebo-controlled, double-blind Phase IIb clinical trial in patients with difficult tibial fractures has received approval from regulatory authorities in six of the seven planned European countries to date, and is expected to enroll the first patient later this year.

About Link Health Pharma Co., Ltd

Link Health is a leading Chinese pharmaceutical company based in Guangzhou, Southern China, focusing on the development of innovative drugs for unmet medical needs.

Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently. The company has a drug development pipeline of 5 clinical stage assets and 1 under NDA reviewing in China.

The company has also established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office builds and further strengthen collaborations with global pharma/biotech partners and research institutes.

About Pregene Biopharma Co., Ltd

Shenzhen Pregene Biopharma Co. Ltd is a leading enterprise in the cell and gene therapy field with the core technology for industrialization. The companys core team comes from well-known institutions and companies including the Academy of Military Medical Sciences, the University of Toronto, and the US FDA.

Pregene has established the gene editing platform, viral vector and cell production platform, nanobody selection platform and other small to pilot trial manufacturing system, with total investment over 100 million CNY. It has the laboratories and GMP plants for cell and gene therapy of over 10,000 square meter.

The company focuses on the research and development of cell and gene therapy drugs, and participated in the drafting the national standard Considerations for CAR-T Cell Quality Study and Non-clinical Evaluation issued by the National Institutes for Food and Drug Control in June 2018. The CAR-T cell therapy for the treatment of multiple myeloma have obtained NMPA IND clearance as the Class I new drug, which is the first in China and fastest in the world using the humanized single domain antibody in CAR construct, and phase I clinical trials are now in progress. Other pipelines such as CAR-T, TCR-T and mRNA drugs for tumors, autoimmune diseases and other indications are in the development at different stages. The company has broad development prospects with the abundant backup technologies.

Looking forward to the future, the company will build the core capacity in one-stop solution for cell and gene therapy drugs, and fulfill the Express of innovative medicine development from drug discovery to clinical products.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available atwww.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SA Miguel Forte, MD, PhD, Chief Executive Officer Jean-Luc Vandebroek, Chief Financial Officer Tel: +32 (0)71 12 10 00 investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries: Bepublic Catherine Haquenne Tel: +32 (0)497 75 63 56 catherine@bepublic.be

International Media Enquiries: Image Box Communications Neil Hunter / Michelle Boxall Tel: +44 (0)20 8943 4685 neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouill Tel: +33 (0)1 44 71 94 94 bone@newcap.eu

For US Media and Investor Enquiries: LHA Investor Relations Yvonne Briggs Tel: +1 310 691 7100 ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Read more from the original source:
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -...

NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank – PRNewswire

By Stell Cell Research

MINNEAPOLIS, Oct. 6, 2020 /PRNewswire/ --The National Marrow Donor Program (NMDP)/Be The Match today announced a collaboration with the Minnesota health system M Health Fairview and Marcus Center for Cellular Cures (MC3)/Carolinas Cord Blood Bank at Duke University (Duke) to offer cryopreservation services to transplant centers through the Be The Match BioBank. The collaboration brings together industry-leading expertise in cryopreservation and storage of patient-directed donor blood stem cell products to improve donor availability, collection quality, and ultimately, to provide a more reliable path to transplant for patients.

Through the Be The Match BioBank, blood stem cell donors will be able to donate bone marrow or peripheral blood stem cells (PBSC) for an intended patient on a timeline that is convenient for the donor. The cells are then cryopreserved and stored for the transplant center at no cost to them and shipped to coincide with initiation of the patient's conditioning regimen and optimal treatment timeline.

"We're excited to expand our partnership with Duke University by adding the expertise of physicians and researchers at M Health Fairview University of Minnesota Medical Center to continue to overcome logistical barriers to blood and marrow transplantation that might otherwise disrupt optimal patient care. Through the flexibility offered by the Be The Match BioBank, we believe we can provide transplant centers with a well-matched, available donor more often, and allow the transplant to occur at the best time for the patient," explained Steven Devine, MD, Chief Medical Officer, NMDP/Be The Match, and Associate Scientific Director, CIBMTR (Center for International Blood and Marrow Transplant Research). "The team at the Duke University lab was instrumental in the development of the Be The Match BioBank, as well as supporting donor product cryopreservation during the COVID-19 pandemic to ensure patients can continue to receive the transplants they need."

"We are proud to extend our partnership with the NMDP/Be The Match in a new way. Be The Match BioBank is an innovative way to remove barriers that otherwise may stand in the way of a patient's transplant," said Joanne Kurtzberg, MD, who leads the Marcus Center for Cellular Cures (MC3)/Carolinas Cord Blood Bank at Duke University.

"We are thrilled to be working with the NMDP/Be The Match to offer Be The Match BioBank. Through this partnership, transplant physicians can have confidence a high-quality bone marrow or PBSC product will be available from the donor they requested in the timeframe that works best for their patient," said David McKenna, MD, who leads the Molecular and Cellular Therapeutics program at M Health Fairview.

Be The Match BioBank can be used by any transplant center in the NMDP/Be The Match Network of more than 180 transplant centers worldwide. Blood stem cell donors are informed that the transplant center is requesting cryopreservation and provide consent prior to collection. Donors can also consent to having their donated cells made available to other searching patients in the unlikely event the intended patient is unable to proceed to transplant as planned.

To learn more about Be The Match BioBank, visit Network.BeTheMatchClinical.org/BioBank.

About the National Marrow Donor Program/Be The Match The National Marrow Donor Program/Be The Match is the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia and lymphoma, as well as other diseases. The organization manages the world's largest registry of potential blood stem cell donors and cord blood units. The NMDP/Be The Match partners with a global network to connect patients to their donor match for a transplant, and provides education and support for patients. Through Be The Match BioTherapies, the NMDP/Be The Match partners with cell and gene therapy companies to support the development and delivery of new therapies. The organization conducts research through its research program, CIBMTR (Center for International Blood and Marrow Transplant Research), in collaboration with Medical College of Wisconsin.

About M Health Fairview M Health Fairview is the newly expanded collaboration betweenthe University of Minnesota, University of Minnesota Physicians,and Fairview Health Services. The healthcare system combines the best of academic and community medicine expanding access to world-class, breakthrough care through its 10 hospitals and 60 clinics.

SOURCE Be The Match

Read more from the original source:
NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - PRNewswire

Neural Stem Cells Market size and Key Trends in terms of volume and value 2020- – News by aeresearch

By Stell Cell Research

Global Neural Stem Cells Market research report provides and in-depth analysis on industry and economy-wide database for business management that could potentially offer development and profitability for players in this market. The Neural Stem Cells market report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, regions, demand and developments.

The Neural Stem Cells market report contains a holistic analysis of this business domain, with respect to the key growth drivers, opportunities, and restraints. The document scrutinizes the impact of COVID-19 pandemic on the growth matrix of this vertical. Moreover, it provides crucial information regarding the competitive landscape and assesses popular tactics employed by leading participants in order to adapt to the market instabilities.

Major highlights from COVID-19 impact analysis:

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/320130

An overview of the regional analysis:

Additional highlights from the Neural Stem Cells market report:

Key Questions Answered:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/320130

Read more here:
Neural Stem Cells Market size and Key Trends in terms of volume and value 2020- - News by aeresearch

Stem Cell Characterization and Analysis Tool Market Set to Witness an Uptick during 2020 2026 – The Daily Chronicle

By Stell Cell Research

The Stem Cell Characterization and Analysis Tool Market study offers a whole investigation of the Industry that contains authenticities, experiences, authentic information, and factually upheld and industry-approved market data. Stem Cell Characterization and Analysis Tool Market report conjointly contains estimates that are gotten from reliable sources and practices.

Stem Cell Characterization and Analysis Tool Industry Segmentation

The whole Stem Cell Characterization and Analysis Tool market has been sub-sorted by segments and subsegments. The report offers an examination of those subsections concerning the provincial division. This market research report can keep marketers refined and assist them in making informed business decisions and gain a competitive edge in the market over their competitors.

The Stem Cell Characterization and Analysis Tool market can be segmented:

By Companies: Osiris Therapeutics, Inc., Cytori Therapeutics, Inc., Astellas Pharma Inc., Caladrius Biosciences, Inc., Cellular Engineering Technologies Inc., U.S. Stem Cell, Inc., BioTime Inc., TEMCELL Technologies Inc., BrainStorm Cell Therapeutics Inc.

By Types: Services, Software, Instruments, Accessories, Consumables, Reagent and Assay Kits

By Application: Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Other Therapeutic Applications, Drug Development and Discovery Embryonic Stem Cells Research

Get Instant Sample [emailprotected] https://www.regalintelligence.com/request-sample/170873

This Stem Cell Characterization and Analysis Tool market report is submitted the far-reaching utilization of both primary and secondary information sources. The market research report incorporates the investigation of numerous components that are impacting the business, along with the govt strategy, current situation and market condition, patterns inside the market, future innovations, and specialized advancement in associated ventures, and market opportunities, market obstructions, and difficulties.

With figures and tables, the report studies the Stem Cell Characterization and Analysis Tool Industry. This investigation conveys key measurements on the condition of the market and could be an important information source for creators and individuals inquisitive about this market. The report conjointly offers late market elements, such as driving factors, limiting elements, and market news, for example, mergers, ventures, and acquisitions. It offers market size (volume and worth), market income, development rate, and incorporates each quantitative and subjective methodologies to make assessments in various districts or nations.

The report on Stem Cell Characterization and Analysis Tool market will help in understanding the business to construct ways for business development in a likely manner. Inside the report, it furthermore offers bits of knowledge from advancing channel to potential development methodologies, giving top to bottom investigation of dominating players in the Stem Cell Characterization and Analysis Tool market.

Enquire about this [emailprotected] https://www.regalintelligence.com/enquiry/170873

1 Report Overview 1.1 Study Scope and Definition 1.2 Research Methodology 1.2.1 Methodology/Research Approach 1.2.2 Data Source 1.3 Key Market Segments 1.4 Players Covered: Ranking by Stem Cell Characterization and Analysis Tool Revenue 1.5 Market Analysis by Type 1.5.1 Global Stem Cell Characterization and Analysis Tool Market Size Growth Rate by Type: 2020 VS 2026 1.5.2 Services 1.5.3 Software 1.5.4 Instruments 1.5.5 Accessories 1.5.6 Consumables 1.5.7 Reagent and Assay Kits 1.6 Market by Application 1.6.1 Global Stem Cell Characterization and Analysis Tool Market Share by Application: 2021-2026 1.6.2 Neurological Disorders 1.6.3 Orthopedic Treatments 1.6.4 Oncology Disorders 1.6.5 Diabetes 1.6.6 Other Therapeutic Applications 1.6.7 Drug Development and Discovery Embryonic Stem Cells Research 1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.7.2 Covid-19 Impact: Commodity Prices Indices 1.7.3 Covid-19 Impact: Global Major Government Policy 1.8 Study Objectives 1.9 Years Considered 2 Global Stem Cell Characterization and Analysis Tool Market Trends and Growth Strategy 2.1 Market Top Trends 2.2 Market Drivers 2.3 Market Challenges 2.4 Porters Five Forces Analysis 2.5 Market Growth Strategy 2.6 SWOT Analysis 3 Global Stem Cell Characterization and Analysis Tool Market Players Profiles 3.1 Osiris Therapeutics, Inc. 3.1.1 Osiris Therapeutics, Inc. Company Profile 3.1.2 Osiris Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.1.3 Osiris Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.2 Cytori Therapeutics, Inc. 3.2.1 Cytori Therapeutics, Inc. Company Profile 3.2.2 Cytori Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.2.3 Cytori Therapeutics, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.3 Astellas Pharma Inc. 3.3.1 Astellas Pharma Inc. Company Profile 3.3.2 Astellas Pharma Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.3.3 Astellas Pharma Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.4 Caladrius Biosciences, Inc. 3.4.1 Caladrius Biosciences, Inc. Company Profile 3.4.2 Caladrius Biosciences, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.4.3 Caladrius Biosciences, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.5 Cellular Engineering Technologies Inc. 3.5.1 Cellular Engineering Technologies Inc. Company Profile 3.5.2 Cellular Engineering Technologies Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.5.3 Cellular Engineering Technologies Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.6 U.S. Stem Cell, Inc. 3.6.1 U.S. Stem Cell, Inc. Company Profile 3.6.2 U.S. Stem Cell, Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.6.3 U.S. Stem Cell, Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.7 BioTime Inc. 3.7.1 BioTime Inc. Company Profile 3.7.2 BioTime Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.7.3 BioTime Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.8 TEMCELL Technologies Inc. 3.8.1 TEMCELL Technologies Inc. Company Profile 3.8.2 TEMCELL Technologies Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.8.3 TEMCELL Technologies Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 3.9 BrainStorm Cell Therapeutics Inc. 3.9.1 BrainStorm Cell Therapeutics Inc. Company Profile 3.9.2 BrainStorm Cell Therapeutics Inc. Stem Cell Characterization and Analysis Tool Product Specification 3.9.3 BrainStorm Cell Therapeutics Inc. Stem Cell Characterization and Analysis Tool Production Capacity, Revenue, Price and Gross Margin (2015-2020) 4 Global Stem Cell Characterization and Analysis Tool Market Competition by Market Players 4.1 Global Stem Cell Characterization and Analysis Tool Production Capacity Market Share by Market Players (2015-2020) 4.2 Global Stem Cell Characterization and Analysis Tool Revenue Market Share by Market Players (2015-2020) 4.3 Global Stem Cell Characterization and Analysis Tool Average Price by Market Players (2015-2020) 5 Global Stem Cell Characterization and Analysis Tool Production by Regions (2015-2020) 5.1 North America 5.1.1 North America Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.1.2 Stem Cell Characterization and Analysis Tool Key Players in North America (2015-2020) 5.1.3 North America Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.1.4 North America Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.2 East Asia 5.2.1 East Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.2.2 Stem Cell Characterization and Analysis Tool Key Players in East Asia (2015-2020) 5.2.3 East Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.2.4 East Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.3 Europe 5.3.1 Europe Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.3.2 Stem Cell Characterization and Analysis Tool Key Players in Europe (2015-2020) 5.3.3 Europe Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.3.4 Europe Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.4 South Asia 5.4.1 South Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.4.2 Stem Cell Characterization and Analysis Tool Key Players in South Asia (2015-2020) 5.4.3 South Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.4.4 South Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.5 Southeast Asia 5.5.1 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.5.2 Stem Cell Characterization and Analysis Tool Key Players in Southeast Asia (2015-2020) 5.5.3 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.5.4 Southeast Asia Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.6 Middle East 5.6.1 Middle East Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.6.2 Stem Cell Characterization and Analysis Tool Key Players in Middle East (2015-2020) 5.6.3 Middle East Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.6.4 Middle East Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.7 Africa 5.7.1 Africa Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.7.2 Stem Cell Characterization and Analysis Tool Key Players in Africa (2015-2020) 5.7.3 Africa Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.7.4 Africa Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.8 Oceania 5.8.1 Oceania Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.8.2 Stem Cell Characterization and Analysis Tool Key Players in Oceania (2015-2020) 5.8.3 Oceania Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.8.4 Oceania Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.9 South America 5.9.1 South America Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.9.2 Stem Cell Characterization and Analysis Tool Key Players in South America (2015-2020) 5.9.3 South America Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.9.4 South America Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 5.10 Rest of the World 5.10.1 Rest of the World Stem Cell Characterization and Analysis Tool Market Size (2015-2020) 5.10.2 Stem Cell Characterization and Analysis Tool Key Players in Rest of the World (2015-2020) 5.10.3 Rest of the World Stem Cell Characterization and Analysis Tool Market Size by Type (2015-2020) 5.10.4 Rest of the World Stem Cell Characterization and Analysis Tool Market Size by Application (2015-2020) 6 Global Stem Cell Characterization and Analysis Tool Consumption by Region (2015-2020) 6.1 North America 6.1.1 North America Stem Cell Characterization and Analysis Tool Consumption by Countries 6.1.2 United States 6.1.3 Canada 6.1.4 Mexico 6.2 East Asia 6.2.1 East Asia Stem Cell Characterization and Analysis Tool Consumption by Countries 6.2.2 China 6.2.3 Japan 6.2.4 South Korea 6.3 Europe 6.3.1 Europe Stem Cell Characterization and Analysis Tool Consumption by Countries 6.3.2 Germany 6.3.3 United Kingdom 6.3.4 France 6.3.5 Italy 6.3.6 Russia 6.3.7 Spain 6.3.8 Netherlands 6.3.9 Switzerland 6.3.10 Poland 6.4 South Asia 6.4.1 South Asia Stem Cell Characterization and Analysis Tool Consumption by Countries 6.4.2 India 6.5 Southeast Asia 6.5.1 Southeast Asia Stem Cell Characterization and Analysis Tool Consumption by Countries 6.5.2 Indonesia 6.5.3 Thailand 6.5.4 Singapore 6.5.5 Malaysia 6.5.6 Philippines 6.6 Middle East 6.6.1 Middle East Stem Cell Characterization and Analysis Tool Consumption by Countries 6.6.2 Turkey 6.6.3 Saudi Arabia 6.6.4 Iran 6.6.5 United Arab Emirates 6.7 Africa 6.7.1 Africa Stem Cell Characterization and Analysis Tool Consumption by Countries 6.7.2 Nigeria 6.7.3 South Africa 6.8 Oceania 6.8.1 Oceania Stem Cell Characterization and Analysis Tool Consumption by Countries 6.8.2 Australia 6.9 South America 6.9.1 South America Stem Cell Characterization and Analysis Tool Consumption by Countries 6.9.2 Brazil 6.9.3 Argentina 6.10 Rest of the World 6.10.1 Rest of the World Stem Cell Characterization and Analysis Tool Consumption by Countries 7 Global Stem Cell Characterization and Analysis Tool Production Forecast by Regions (2021-2026) 7.1 Global Forecasted Production of Stem Cell Characterization and Analysis Tool (2021-2026) 7.2 Global Forecasted Revenue of Stem Cell Characterization and Analysis Tool (2021-2026) 7.3 Global Forecasted Price of Stem Cell Characterization and Analysis Tool (2021-2026) 7.4 Global Forecasted Production of Stem Cell Characterization and Analysis Tool by Region (2021-2026) 7.4.1 North America Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.2 East Asia Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.3 Europe Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.4 South Asia Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.5 Southeast Asia Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.6 Middle East Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.7 Africa Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.8 Oceania Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.9 South America Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.4.10 Rest of the World Stem Cell Characterization and Analysis Tool Production, Revenue Forecast (2021-2026) 7.5 Forecast by Type and by Application (2021-2026) 7.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026) 7.5.2 Global Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Application (2021-2026) 8 Global Stem Cell Characterization and Analysis Tool Consumption Forecast by Regions (2021-2026) 8.1 North America Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.2 East Asia Market Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.3 Europe Market Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Countriy 8.4 South Asia Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.5 Southeast Asia Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.6 Middle East Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.7 Africa Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.8 Oceania Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.9 South America Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 8.10 Rest of the world Forecasted Consumption of Stem Cell Characterization and Analysis Tool by Country 9 Global Stem Cell Characterization and Analysis Tool Sales by Type (2015-2026) 9.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Type (2015-2020) 9.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Type (2021-2026) 10 Global Stem Cell Characterization and Analysis Tool Consumption by Application (2015-2026) 10.1 Global Stem Cell Characterization and Analysis Tool Historic Market Size by Application (2015-2020) 10.2 Global Stem Cell Characterization and Analysis Tool Forecasted Market Size by Application (2021-2026) 11 Global Stem Cell Characterization and Analysis Tool Manufacturing Cost Analysis 11.1 Stem Cell Characterization and Analysis Tool Key Raw Materials Analysis 11.1.1 Key Raw Materials 11.2 Proportion of Manufacturing Cost Structure 11.3 Manufacturing Process Analysis of Stem Cell Characterization and Analysis Tool 12 Global Stem Cell Characterization and Analysis Tool Marketing Channel, Distributors, Customers and Supply Chain 12.1 Marketing Channel 12.2 Stem Cell Characterization and Analysis Tool Distributors List 12.3 Stem Cell Characterization and Analysis Tool Customers 12.4 Stem Cell Characterization and Analysis Tool Supply Chain Analysis 13 Analyst's Viewpoints/Conclusions 14 Disclaimer

Get Detailed Table of Contents: https://www.regalintelligence.com/request-toc/170873

The report contains Porters 5 Forces Model, Value Chain Analysis, and Market Pull Analysis. These devices encourage to get a straightforward picture of the business structure and evaluate the market quality at a global level. Moreover, these apparatuses conjointly present a total investigation of product application inside the worldwide Stem Cell Characterization and Analysis Tool Industry.

Here is the original post:
Stem Cell Characterization and Analysis Tool Market Set to Witness an Uptick during 2020 2026 - The Daily Chronicle

→←